Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
2003 1
2007 1
2008 13
2009 1
2010 3
2011 8
2012 14
2013 10
2014 9
2015 11
2016 16
2017 35
2018 30
2019 46
2020 86
2021 99
2022 103
2023 95
2024 37

Text availability

Article attribute

Article type

Publication date

Search Results

531 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Promises of microbiome-based therapies.
Bajaj JS, Ng SC, Schnabl B. Bajaj JS, et al. J Hepatol. 2022 Jun;76(6):1379-1391. doi: 10.1016/j.jhep.2021.12.003. J Hepatol. 2022. PMID: 35589257 Free PMC article. Review.
Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
Ding GY, Ma JQ, Yun JP, Chen X, Ling Y, Zhang S, Shi JY, Chang YQ, Ji Y, Wang XY, Tan WM, Yuan KF, Yan B, Zhang XM, Liang F, Zhou J, Fan J, Zeng Y, Cai MY, Gao Q. Ding GY, et al. J Hepatol. 2022 Mar;76(3):608-618. doi: 10.1016/j.jhep.2021.10.030. Epub 2021 Nov 15. J Hepatol. 2022. PMID: 34793865
RESULTS: A quaternary TLS scoring system was established for the intra-tumor region (T score) and peri-tumor region (P score) respectively. T scores positively correlated with favorable prognosis (p <0.001), whereas a high P score signified worse survival …
RESULTS: A quaternary TLS scoring system was established for the intra-tumor region (T score) and peri-tumor region (P score) respect …
Augmenter of liver regeneration: Mitochondrial function and steatohepatitis.
Verma AK, Sharma A, Subramaniyam N, Gandhi CR. Verma AK, et al. J Hepatol. 2022 Nov;77(5):1410-1421. doi: 10.1016/j.jhep.2022.06.019. Epub 2022 Jun 28. J Hepatol. 2022. PMID: 35777586 Review.
ALR's FAD-linked sulfhydryl oxidase activity is essential for protein folding in the mitochondrial intermembrane space. ALR's functions also include cytochrome c reductase and protein Fe/S maturation activities. ALR depletion from hepatocytes leads to increased oxidative s …
ALR's FAD-linked sulfhydryl oxidase activity is essential for protein folding in the mitochondrial intermembrane space. ALR's functions also …
PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
Wei CY, Zhu MX, Zhang PF, Huang XY, Wan JK, Yao XZ, Hu ZT, Chai XQ, Peng R, Yang X, Gao C, Gao J, Wang SW, Zheng YM, Tang Z, Gao Q, Zhou J, Fan JB, Ke AW, Fan J. Wei CY, et al. J Hepatol. 2022 Jul;77(1):163-176. doi: 10.1016/j.jhep.2022.02.019. Epub 2022 Feb 24. J Hepatol. 2022. PMID: 35219791 Free article.
Mechanistically, we primarily demonstrated that protein kinase C alpha (PKCalpha) directly phosphorylates ZFP64 at S226, leading to its nuclear translocation and the transcriptional activation of macrophage colony-stimulating factor (CSF1). ...
Mechanistically, we primarily demonstrated that protein kinase C alpha (PKCalpha) directly phosphorylates ZFP64 at S226, leading to i …
ARDD 2020: from aging mechanisms to interventions.
Mkrtchyan GV, Abdelmohsen K, Andreux P, Bagdonaite I, Barzilai N, Brunak S, Cabreiro F, de Cabo R, Campisi J, Cuervo AM, Demaria M, Ewald CY, Fang EF, Faragher R, Ferrucci L, Freund A, Silva-García CG, Georgievskaya A, Gladyshev VN, Glass DJ, Gorbunova V, de Grey A, He WW, Hoeijmakers J, Hoffmann E, Horvath S, Houtkooper RH, Jensen MK, Jensen MB, Kane A, Kassem M, de Keizer P, Kennedy B, Karsenty G, Lamming DW, Lee KF, MacAulay N, Mamoshina P, Mellon J, Molenaars M, Moskalev A, Mund A, Niedernhofer L, Osborne B, Pak HH, Parkhitko A, Raimundo N, Rando TA, Rasmussen LJ, Reis C, Riedel CG, Franco-Romero A, Schumacher B, Sinclair DA, Suh Y, Taub PR, Toiber D, Treebak JT, Valenzano DR, Verdin E, Vijg J, Young S, Zhang L, Bakula D, Zhavoronkov A, Scheibye-Knudsen M. Mkrtchyan GV, et al. Aging (Albany NY). 2020 Dec 30;12(24):24484-24503. doi: 10.18632/aging.202454. Epub 2020 Dec 30. Aging (Albany NY). 2020. PMID: 33378272 Free PMC article. Review.
More than 2000 participants and 65 speakers joined the meeting and we already look forward to an even larger meeting next year. Please mark your calendars for the 8(th) ARDD meeting that is scheduled for the 31(st) of August to 3(rd) of September, 2021, at Columbia Univers …
More than 2000 participants and 65 speakers joined the meeting and we already look forward to an even larger meeting next year. Please …
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Harrison SA, Ruane PJ, Freilich B, Neff G, Patil R, Behling C, Hu C, Shringarpure R, de Temple B, Fong E, Tillman EJ, Rolph T, Cheng A, Yale K. Harrison SA, et al. JHEP Rep. 2022 Aug 23;5(1):100563. doi: 10.1016/j.jhepr.2022.100563. eCollection 2023 Jan. JHEP Rep. 2022. PMID: 36644237 Free PMC article.
BACKGROUND & AIMS: Efruxifermin has shown clinical efficacy in patients with non-alcoholic steatohepatitis (NASH) and F1-F3 fibrosis. The primary objective of the BALANCED Cohort C was to assess the safety and tolerability of efruxifermin in patients with compensated N …
BACKGROUND & AIMS: Efruxifermin has shown clinical efficacy in patients with non-alcoholic steatohepatitis (NASH) and F1-F3 fibrosis. Th …
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse.
Hogan LE, Brown PA, Ji L, Xu X, Devidas M, Bhatla T, Borowitz MJ, Raetz EA, Carroll A, Heerema NA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Hunger SP, Loh ML. Hogan LE, et al. J Clin Oncol. 2023 Sep 1;41(25):4118-4129. doi: 10.1200/JCO.22.02200. Epub 2023 May 31. J Clin Oncol. 2023. PMID: 37257143 Clinical Trial.
RESULTS: The 4-year DFS/OS for the 255 LR patients accrued between December 2014 and September 2019 were 61.2% 5.0%/90.4% 3.0% for blinatumomab versus 49.5% 5.2%/79.6% 4.3% for chemotherapy (P = .089/P = .11). For bone marrow (BM) extramedullary (EM) (BM EM; n = 174 …
RESULTS: The 4-year DFS/OS for the 255 LR patients accrued between December 2014 and September 2019 were 61.2% 5.0%/90.4% 3.0% for blinatumo …
PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.
Yu M, Chen Z, Zhou Q, Zhang B, Huang J, Jin L, Zhou B, Liu S, Yan J, Li X, Zhang W, Liu C, Hu B, Fu P, Zhou C, Xu Y, Xiao Y, Zhou J, Fan J, Ren N, Hung MC, Guo L, Li H, Ye Q. Yu M, et al. J Hepatol. 2022 Jul;77(1):140-151. doi: 10.1016/j.jhep.2022.01.026. Epub 2022 Feb 12. J Hepatol. 2022. PMID: 35157958
Microarray analysis was used to evaluate the pathological relevance of the PARG/DDB1/c-Myc/MMR axis. RESULTS: High PARG expression was strongly associated with poor HCC prognosis. ...PARG promoted HCC growth and metastasis through DDB1-dependent modulation of c-Myc. …
Microarray analysis was used to evaluate the pathological relevance of the PARG/DDB1/c-Myc/MMR axis. RESULTS: High PARG expression wa …
Macrophage CD5L is a target for cancer immunotherapy.
Sanchez-Moral L, Paul T, Martori C, Font-Díaz J, Sanjurjo L, Aran G, Téllez É, Blanco J, Carrillo J, Ito M, Tuttolomondo M, Ditzel HJ, Fumagalli C, Tapia G, Sidorova J, Masnou H, Fernández-Sanmartín MA, Lozano JJ, Vilaplana C, Rodriguez-Cortés A, Armengol C, Valledor AF, Kremer L, Sarrias MR. Sanchez-Moral L, et al. EBioMedicine. 2023 May;91:104555. doi: 10.1016/j.ebiom.2023.104555. Epub 2023 Apr 11. EBioMedicine. 2023. PMID: 37054630 Free PMC article.
Accordingly, high TAM expression of CD5L in PAC was associated with poor patient outcome (Log-rank (Mantel-Cox) test p = 0.02). We raised a new anti-CD5L mAb that blocked the immunosuppressive phenotype of macrophages in vitro. ...INTERPRETATION: CD5L protein plays a key f …
Accordingly, high TAM expression of CD5L in PAC was associated with poor patient outcome (Log-rank (Mantel-Cox) test p = 0.02). We ra …
Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
Boursier J, Hagström H, Ekstedt M, Moreau C, Bonacci M, Cure S, Ampuero J, Nasr P, Tallab L, Canivet CM, Kechagias S, Sánchez Y, Dincuff E, Lucena A, Roux M, Riou J, Trylesinski A, Romero-Gomez M. Boursier J, et al. J Hepatol. 2022 May;76(5):1013-1020. doi: 10.1016/j.jhep.2021.12.031. Epub 2022 Jan 19. J Hepatol. 2022. PMID: 35063601
The main study outcome during follow-up was occurrence of LREs, a composite endpoint combining cirrhosis complications and/or hepatocellular carcinoma. Discriminative ability was evaluated using Harrell's C-index. RESULTS: FIB4 and VCTE showed good accuracy for the predict …
The main study outcome during follow-up was occurrence of LREs, a composite endpoint combining cirrhosis complications and/or hepatocellular …
531 results